Coronavirus Disease 2019 (COVID-19)
Conditions
Interventions
routine clinical practice :routine clinical practice
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Confirmed and clinically diagnosed cases of novel coronavirus infection (According to Diagnostic criteria of Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9).
Exclusion criteria
Exclusion criteria: 1. Patients unable to cooperate with the investigation or follow-up; 2. Patients who are unable to complete informed consent; 3. Refusing to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health-Related Quality of Life;Lung function;Sequelae of COVID-19;In-hospital death;Clinical improvement;Frailty assessment;readmission;female fertility;male fertility;covid-19 related complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical signs and symptoms;TCM symptom scale;Pulmonary CT;Modified British Medical Research Council(mMRC);Exercise tolerance;Chest image;Extrapulmonary organ function;Mental health;Working state;Severe outcome;ICU admission;Mechanical ventilation;Disease severity;Length of stay;Antibody titer;seropositivity;Cytoinflammatory factor;Markers of myocardial injury;Heart failure marker;Liver and kidney function;Mini-Mental State Exam(MMSE);Hospital Anxiety and Depression Scale(HADS);Patient Health Questionnaire-9 (PHQ-9);The Pittsburgh Sleep Quality Index (PSQI);Number of outpatient visits after discharge;pace;Grip strength;muscle and fat;MNA;Nutritional risk screening (NRS 2002);Risk of thrombosis and tendency to bleed;Fall assessment scale;Thrombus score;Lymphocyte function;Activity of Daily Living(ADL);Multiple Organ Dysfunction Score(MODS);Fecal routine and occult blood;Hb;BUN;electrocardiogram;D-dimer;Troponin T;Use of medical resources after discharge;death;IL-1;IL-6;IL-15;TNFa;CRP;Platelet-related parameters;Drug metabolism gene;Immunological index;Lymphocyte subsets;Immunosenescence index;senescence-associated secretory phenotype(SASP);NLR;EQ-5D;Monash Comprehensive Nutrition Assessment Questionnaire(CNAQ);Migraine Disability Assessment (MIDAS);VAS score for taste disorders;Drug treatment-related adverse events;Treatment cost;CD4+T cell count;CD8+T cell count; | — |
Countries
China
Contacts
Public ContactJie Qiao
Peking University Third Hospital
Outcome results
None listed